The New England Journal of Medicine publishes the results from a 31-patient 12-week Phase 1 proof-of-concept study of Amgen's (AMGN +0.1%) AMG-157 mAb for asthma. The study's conclusion is that AMG-157 reduced allergen-induced bronchoconstriction and indexes of airway inflammation before and after allergen challenge. The results are statistically significant.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs